Guidelines
Aggrastat® HDB is Class I recommended
in the following guidelines:
1. Amsterdam EA et al. J Am Coll Cardiol 2014;64:2645-2687
2. Levine GN et al. J Am Coll Cardiol 2011;58:e44-e122
1. Amsterdam EA et al. J Am Coll Cardiol 2014;64:2645-2687
2. Levine GN et al. J Am Coll Cardiol 2011;58:e44-e122
Indication:
Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
Contraindications:
Warnings and Precautions:
Adverse Reactions:
For additional information, refer to the full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.FDA.gov/medwatch
or call 1-800-FDA-1088.